Neovasc Inc. (NVCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVCN Stock Summary
- NEOVASC INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 13.21% of US listed stocks.
- With a price/sales ratio of 24.84, NEOVASC INC has a higher such ratio than 94.76% of stocks in our set.
- The volatility of NEOVASC INC's share price is greater than that of 96.97% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to NEOVASC INC, a group of peers worth examining would be ONTX, KOPN, XBIO, BYSI, and HCWB.
- NVCN's SEC filings can be seen here. And to visit NEOVASC INC's official web site, go to www.neovasc.com.
NVCN Valuation Summary
- NVCN's EV/EBIT ratio is -1.8; this is 117.73% lower than that of the median Healthcare stock.
- Over the past 184 months, NVCN's price/sales ratio has gone up 23.4.
Below are key valuation metrics over time for NVCN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NVCN | 2023-01-30 | 24.5 | 2.7 | -2.3 | -1.8 |
| NVCN | 2023-01-27 | 24.5 | 2.7 | -2.3 | -1.8 |
| NVCN | 2023-01-26 | 24.6 | 2.7 | -2.3 | -1.8 |
| NVCN | 2023-01-25 | 24.5 | 2.7 | -2.3 | -1.8 |
| NVCN | 2023-01-24 | 24.5 | 2.7 | -2.3 | -1.8 |
| NVCN | 2023-01-23 | 24.4 | 2.7 | -2.3 | -1.8 |
NVCN Growth Metrics
- Its 4 year net cashflow from operations growth rate is now at 30.18%.
- The 3 year net cashflow from operations growth rate now stands at -6.79%.
- Its 5 year net income to common stockholders growth rate is now at 63.3%.
The table below shows NVCN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 3.111242 | -23.9265 | -33.51675 |
| 2022-06-30 | 2.891351 | -24.98559 | -32.82565 |
| 2022-03-31 | 2.706359 | -25.43355 | -32.88106 |
| 2021-12-31 | 2.547406 | -27.11277 | -24.88907 |
| 2021-09-30 | 2.302284 | -29.37562 | -23.15948 |
| 2021-06-30 | 2.225282 | -30.89349 | -25.85856 |
NVCN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVCN has a Quality Grade of F, ranking ahead of 0.31% of graded US stocks.
- NVCN's asset turnover comes in at 0.14 -- ranking 148th of 184 Medical Equipment stocks.
- 500 - Internal server error
The table below shows NVCN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.140 | 0.772 | -4.860 |
| 2019-12-31 | 0.189 | 0.781 | -4.740 |
| 2018-12-31 | 0.102 | 0.791 | -28.053 |
| 2017-12-31 | 0.089 | 0.355 | 0.408 |
| 2016-12-31 | 0.119 | 0.255 | 1.637 |
| 2015-12-31 | 0.234 | 0.301 | -3.837 |
NVCN Price Target
For more insight on analysts targets of NVCN, see our NVCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
NVCN Stock Price Chart Interactive Chart >
NVCN Price/Volume Stats
| Current price | $28.38 | 52-week high | $28.43 |
| Prev. close | $28.14 | 52-week low | $4.59 |
| Day low | $28.02 | Volume | 31,200 |
| Day high | $28.43 | Avg. volume | 98,881 |
| 50-day MA | $17.96 | Dividend yield | N/A |
| 200-day MA | $9.42 | Market Cap | 77.85M |
Neovasc Inc. (NVCN) Company Bio
Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.
Latest NVCN News From Around the Web
Below are the latest news stories about NEOVASC INC that investors may wish to consider to help them evaluate NVCN as an investment opportunity.
Neovasc Announces German Reimbursement RenewalVANCOUVER and MINNEAPOLIS, Feb. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods (NUBs) are comprised of novel and innovative medicines, medical products and procedure |
5 big deal reports: Sun Pharma’s $576M pact for Concert PharmaBy Davit Kirakosyan |
Shockwave Medical's (SWAV) New Buyout to Boost Patient OutcomeShockwave Medical's (SWAV) latest acquisition is expected to serve a wider patient pool. |
Dow Dinged As Big Bank Earnings WeighA round of earnings from the banking sector is weighing today, stifling Wall Street's early 2023 momentum. |
Shockwave Medical Seeks To Bolster Its Cardiovascular Disease Portfolio With Neovasc AcquisitionShockwave Medical Inc (NASDAQ: SWAV) has agreed to acquire Neovasc Inc (NASDAQ: NVCN) for an upfront cash payment of $27.25 per share, corresponding to an enterprise value of approximately $100 million. The upfront cash consideration represents a 27% and 68% premium to the closing price and 30-day VWAP, respectively, of Neovasc's common shares on Jan. 13, 2023. Neovasc shareholders will also receive a potential deferred payment in the form of a non-tradable contingent value right (CVR), entitlin |
NVCN Price Returns
| 1-mo | 53.57% |
| 3-mo | 335.94% |
| 6-mo | 261.99% |
| 1-year | 142.00% |
| 3-year | -52.30% |
| 5-year | -99.67% |
| YTD | 79.68% |
| 2022 | 34.83% |
| 2021 | -50.76% |
| 2020 | -82.41% |
| 2019 | -9.83% |
| 2018 | -99.00% |
Continue Researching NVCN
Want to do more research on Neovasc Inc's stock and its price? Try the links below:Neovasc Inc (NVCN) Stock Price | Nasdaq
Neovasc Inc (NVCN) Stock Quote, History and News - Yahoo Finance
Neovasc Inc (NVCN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...